 | Up a level |
Massy, Marine; Hoepner, Robert; Pistor, Maximilian (January 2024). Personalisierte MS-Therapie. Forte. Das Magazin der Schweizerischen Multiple Sklerose Gesellschaft(1), pp. 8-10.
Rebsamen, Michael; McKinley, Richard; Radojewski, Piotr; Pistor, Maximilian; Friedli, Christoph; Hoepner, Robert; Salmen, Anke; Chan, Andrew; Reyes, Mauricio; Wagner, Franca; Wiest, Roland; Rummel, Christian (2023). Reliable brain morphometry from contrast-enhanced T1w-MRI in patients with multiple sclerosis. Human brain mapping, 44(3), pp. 970-979. Wiley-Blackwell 10.1002/hbm.26117
Pistor, Maximilian; Seitz, Luca Fabio; Seitz, Pascal (2023). Mit Herz, Hirn und Lunge – Hypereosinophiles Syndrom, eine entzündliche Multisystemerkrankung. Rheuma Schweiz, 3
Hammer, H; Kamber, N; Pistor, M; Diem, L; Friedli, C; Chan, A; Hoepner, R; Salmen, A (2022). Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS). Multiple Sclerosis and Related Disorders, 65, p. 104015. Elsevier 10.1016/j.msard.2022.104015
Pistor, Maximilian; Hammer, Helly; Salmen, Anke; Hoepner, Robert; Friedli, Christoph (2022). Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohort. CNS neuroscience & therapeutics, 28(5), pp. 792-795. Wiley 10.1111/cns.13806
Diem, Lara; Hammer, Helly; Hoepner, Robert; Pistor, Max; Remlinger, Jana; Salmen, Anke (2022). Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD). International Review of Neurobiology, 164, pp. 129-178. 10.1016/bs.irn.2022.06.011
Pistor, Maximilian; Hoepner, Robert; Hoepner, Andreas G F; Lin, Yanan; Jung, Simon; Bassetti, Claudio L; Chan, Andrew; Salmen, Anke (2022). Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System. Therapeutic advances in neurological disorders, 15(17562864221129383), p. 17562864221129383. Sage 10.1177/17562864221129383
Pistor, Maximilian; Salmen, Anke; Chan, Andrew; Hoepner, Robert (2022). COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience. Clinical and translational neuroscience, 6(1), p. 6. MDPI 10.3390/ctn6010006
Pistor, Maximilian; Hoepner, Andreas G F; Lin, Yanan; Jung, Simon; Bassetti, Claudio L; Chan, Andrew; Salmen, Anke; Hoepner, Robert (2021). Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System. Annals of the rheumatic diseases, 80(12), pp. 1633-1635. BMJ Publishing Group 10.1136/annrheumdis-2021-220679
Pistor, Maximilian; Hoffmann, Angelika; Horvath, Thomas; Oberholzer, Michael; Arnold, Marcel; Pilgram-Pastor, Sara Magdalena (2021). Stroke and splenic infarct in a 17-year-old patient with COVID-associated hypercoagulable state and relative ADAMTS13 deficiency. Clinical and translational neuroscience, 5(1), 2514183X2110201. Sage Publications 10.1177/2514183X211020157
Wipke, Brian T; Hoepner, Robert; Strassburger-Krogias, Katrin; Thomas, Ankur M; Gianni, Davide; Szak, Suzanne; Brennan, Melanie S; Pistor, Maximilian; Gold, Ralf; Chan, Andrew; Scannevin, Robert H (2021). Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses. Neurology: Neuroimmunology and Neuroinflammation, 8(2) Wolters Kluwer Health 10.1212/NXI.0000000000000950
Bagnoud, Maud; Briner, Myriam; Remlinger, Jana; Meli, Ivo; Schuetz, Sara; Pistor, Maximilian; Salmen, Anke; Chan, Andrew; Hoepner, Robert (2020). c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis. Cells, 9(10) MDPI 10.3390/cells9102154
Thiele née Schrewe, Lisa; Guse, Kirsten; Tietz, Silvia; Remlinger, Jana; Demir, Seray; Pedreiturria, Xiomara; Hoepner, Robert; Salmen, Anke; Pistor, Maximilian; Turner, Timothy; Engelhardt, Britta; Hermann, Dirk M; Lühder, Fred; Wiese, Stefan; Chan, Andrew (2020). Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. Journal of neuroinflammation, 17(1), p. 9. BioMed Central 10.1186/s12974-019-1677-z
Hoepner, Robert; Bagnoud, Maud; Pistor, Maximilian; Salmen, Anke; Briner, Myriam; Synn, Helen; Schrewe, Lisa; Guse, Kirsten; Ahmadi, Farhad; Demir, Seray; Laverick, Louis; Gresle, Melissa; Worley, Paul; Reichardt, Holger Michael; Butzkueven, Helmut; Gold, Ralf; Metz, Imke; Lühder, Fred; Chan, Andrew (2019). Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta neuropathologica, 138(3), pp. 443-456. Springer-Verlag 10.1007/s00401-019-02018-8
